Cargando…

Bone mineral density in Jamaican men on androgen deprivation therapy for prostate cancer

BACKGROUND: Androgen deprivation therapy (ADT) has been reported to reduce the bone mineral density (BMD) in men with prostate cancer (CaP). However, Afro-Caribbeans are under-represented in most studies. The aim was to determine the effect of androgen deprivation therapy (ADT) on the bone mineral d...

Descripción completa

Detalles Bibliográficos
Autores principales: Morrison, Belinda F, Burrowes, Ingrid E, Aiken, William D, Mayhew, Richard G, Fletcher, Horace M, Reid, Marvin E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3194186/
https://www.ncbi.nlm.nih.gov/pubmed/21992436
http://dx.doi.org/10.1186/1750-9378-6-S2-S7
_version_ 1782213925888065536
author Morrison, Belinda F
Burrowes, Ingrid E
Aiken, William D
Mayhew, Richard G
Fletcher, Horace M
Reid, Marvin E
author_facet Morrison, Belinda F
Burrowes, Ingrid E
Aiken, William D
Mayhew, Richard G
Fletcher, Horace M
Reid, Marvin E
author_sort Morrison, Belinda F
collection PubMed
description BACKGROUND: Androgen deprivation therapy (ADT) has been reported to reduce the bone mineral density (BMD) in men with prostate cancer (CaP). However, Afro-Caribbeans are under-represented in most studies. The aim was to determine the effect of androgen deprivation therapy (ADT) on the bone mineral density (BMD) of men with prostate cancer in Jamaica. METHODS: The study consisted of 346 Jamaican men, over 40 years of age: 133 ADT treated CaP cases (group 1), 43 hormone-naïve CaP controls (group 2) and 170 hormone naïve controls without CaP (group 3). Exclusion criteria included metastatic disease, bisphosphonate therapy or metabolic disease affecting BMD. BMD was measured with a calcaneal ultrasound and expressed in S.D. units relative to young adult men (T score), according to the World Health Organization definition. Patient weight, height and BMI were assessed. RESULTS: Mean ± sd, age of patients in group 1 (75± 7.4 yrs) was significantly greater than groups 2 and 3 (67 ± 8.1 yrs; 65±12.0 yrs). There was no significant difference in weight and BMI between the 3 groups. . The types of ADT (% of cases, median duration in months with IQR) included LHRH (Luteinizing hormone releasing hormone) analogues (28.6%, 17.9, IQR 20.4), oestrogens (9.8%, 60.5, IQR 45.6) anti-androgens (11.3%, 3.3, IQR 15.2) and orchiectomy (15.7%, 43.4, IQR 63.9). Unadjusted t score of group 1, mean ± sd, (-1.6± 1.5) was significantly less than group 2 (-0.9±1.1) and group 3 (-0.7±1.4), p <0.001. Ninety three (69.9%), 20 (45%) and 75 (42%) of patients in groups 1, 2 and 3 respectively were classified as either osteopenic or osteoporotic (p<0.001). Adjusting for age, there was a significant difference in t scores between groups 1 and 2 as well as between groups 1 and 3 (p<0.001). Compared with oestrogen therapy and adjusting for duration of therapy, the odds of low bone mineral density (osteopenia or osteoporosis) with LHRH analogue was 4.5 (95%CI, 14.3 to 3.4); with anti-androgens was 5.9 (95%CI, 32.7 to 5); with orchiectomy was 7.3 (95%CI, 30 to 5.8) and multiple drugs was 9.2 ((95%CI, 31 to 7.1). CONCLUSIONS: ADT is associated with lower BMD in Jamaican men on hormonal therapy for prostate cancer.
format Online
Article
Text
id pubmed-3194186
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-31941862011-10-17 Bone mineral density in Jamaican men on androgen deprivation therapy for prostate cancer Morrison, Belinda F Burrowes, Ingrid E Aiken, William D Mayhew, Richard G Fletcher, Horace M Reid, Marvin E Infect Agent Cancer Proceedings BACKGROUND: Androgen deprivation therapy (ADT) has been reported to reduce the bone mineral density (BMD) in men with prostate cancer (CaP). However, Afro-Caribbeans are under-represented in most studies. The aim was to determine the effect of androgen deprivation therapy (ADT) on the bone mineral density (BMD) of men with prostate cancer in Jamaica. METHODS: The study consisted of 346 Jamaican men, over 40 years of age: 133 ADT treated CaP cases (group 1), 43 hormone-naïve CaP controls (group 2) and 170 hormone naïve controls without CaP (group 3). Exclusion criteria included metastatic disease, bisphosphonate therapy or metabolic disease affecting BMD. BMD was measured with a calcaneal ultrasound and expressed in S.D. units relative to young adult men (T score), according to the World Health Organization definition. Patient weight, height and BMI were assessed. RESULTS: Mean ± sd, age of patients in group 1 (75± 7.4 yrs) was significantly greater than groups 2 and 3 (67 ± 8.1 yrs; 65±12.0 yrs). There was no significant difference in weight and BMI between the 3 groups. . The types of ADT (% of cases, median duration in months with IQR) included LHRH (Luteinizing hormone releasing hormone) analogues (28.6%, 17.9, IQR 20.4), oestrogens (9.8%, 60.5, IQR 45.6) anti-androgens (11.3%, 3.3, IQR 15.2) and orchiectomy (15.7%, 43.4, IQR 63.9). Unadjusted t score of group 1, mean ± sd, (-1.6± 1.5) was significantly less than group 2 (-0.9±1.1) and group 3 (-0.7±1.4), p <0.001. Ninety three (69.9%), 20 (45%) and 75 (42%) of patients in groups 1, 2 and 3 respectively were classified as either osteopenic or osteoporotic (p<0.001). Adjusting for age, there was a significant difference in t scores between groups 1 and 2 as well as between groups 1 and 3 (p<0.001). Compared with oestrogen therapy and adjusting for duration of therapy, the odds of low bone mineral density (osteopenia or osteoporosis) with LHRH analogue was 4.5 (95%CI, 14.3 to 3.4); with anti-androgens was 5.9 (95%CI, 32.7 to 5); with orchiectomy was 7.3 (95%CI, 30 to 5.8) and multiple drugs was 9.2 ((95%CI, 31 to 7.1). CONCLUSIONS: ADT is associated with lower BMD in Jamaican men on hormonal therapy for prostate cancer. BioMed Central 2011-09-23 /pmc/articles/PMC3194186/ /pubmed/21992436 http://dx.doi.org/10.1186/1750-9378-6-S2-S7 Text en Copyright ©2011 Morrison et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Proceedings
Morrison, Belinda F
Burrowes, Ingrid E
Aiken, William D
Mayhew, Richard G
Fletcher, Horace M
Reid, Marvin E
Bone mineral density in Jamaican men on androgen deprivation therapy for prostate cancer
title Bone mineral density in Jamaican men on androgen deprivation therapy for prostate cancer
title_full Bone mineral density in Jamaican men on androgen deprivation therapy for prostate cancer
title_fullStr Bone mineral density in Jamaican men on androgen deprivation therapy for prostate cancer
title_full_unstemmed Bone mineral density in Jamaican men on androgen deprivation therapy for prostate cancer
title_short Bone mineral density in Jamaican men on androgen deprivation therapy for prostate cancer
title_sort bone mineral density in jamaican men on androgen deprivation therapy for prostate cancer
topic Proceedings
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3194186/
https://www.ncbi.nlm.nih.gov/pubmed/21992436
http://dx.doi.org/10.1186/1750-9378-6-S2-S7
work_keys_str_mv AT morrisonbelindaf bonemineraldensityinjamaicanmenonandrogendeprivationtherapyforprostatecancer
AT burrowesingride bonemineraldensityinjamaicanmenonandrogendeprivationtherapyforprostatecancer
AT aikenwilliamd bonemineraldensityinjamaicanmenonandrogendeprivationtherapyforprostatecancer
AT mayhewrichardg bonemineraldensityinjamaicanmenonandrogendeprivationtherapyforprostatecancer
AT fletcherhoracem bonemineraldensityinjamaicanmenonandrogendeprivationtherapyforprostatecancer
AT reidmarvine bonemineraldensityinjamaicanmenonandrogendeprivationtherapyforprostatecancer